Aberrant calcium channel splicing drives defects in cortical differentiation in Timothy syndrome

The syndromic autism spectrum disorder (ASD) Timothy syndrome (TS) is caused by a point mutation in the alternatively spliced exon 8A of the calcium channel Ca 1.2. Using mouse brain and human induced pluripotent stem cells (iPSCs), we provide evidence that the TS mutation prevents a normal developm...

Full description

Saved in:
Bibliographic Details
Published ineLife Vol. 8
Main Authors Panagiotakos, Georgia, Haveles, Christos, Arjun, Arpana, Petrova, Ralitsa, Rana, Anshul, Portmann, Thomas, Paşca, Sergiu P, Palmer, Theo D, Dolmetsch, Ricardo E
Format Journal Article
LanguageEnglish
Published England eLife Science Publications, Ltd 23.12.2019
eLife Sciences Publications Ltd
eLife Sciences Publications, Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The syndromic autism spectrum disorder (ASD) Timothy syndrome (TS) is caused by a point mutation in the alternatively spliced exon 8A of the calcium channel Ca 1.2. Using mouse brain and human induced pluripotent stem cells (iPSCs), we provide evidence that the TS mutation prevents a normal developmental switch in Ca 1.2 exon utilization, resulting in persistent expression of gain-of-function mutant channels during neuronal differentiation. In iPSC models, the TS mutation reduces the abundance of SATB2-expressing cortical projection neurons, leading to excess CTIP2+ neurons. We show that expression of TS-Ca 1.2 channels in the embryonic mouse cortex recapitulates these differentiation defects in a calcium-dependent manner and that Ca 1.2 gain-and-loss of function reciprocally regulates the abundance of these neuronal populations. Our findings support the idea that disruption of developmentally regulated calcium channel splicing patterns instructively alters differentiation in the developing cortex, providing important insights into the pathophysiology of a syndromic ASD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Neucyte, Inc, San Carlos, United States.
Novartis Institutes for Biomedical Research, Cambridge, United States.
Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States.
ISSN:2050-084X
2050-084X
DOI:10.7554/elife.51037